https://www.selleckchem.com/pr....oducts/ap-3-a4-enobl
On multivariate analysis, the presence of a HM II device was associated with a 4-fold increased risk of bleeding. We found the use of enoxaparin "bridge" therapy to be associated with a higher incidence of bleeding in patients with a HM II device compared with an HVAD device. Assessment of device- and patient-specific factors should be evaluated to minimize bleeding events. We found the use of enoxaparin "bridge" therapy to be associated with a higher incidence of bleeding in patients with a HM II device compared with an HVAD d